NeOnc Technologies Holdings Announces Insider Buying, FDA Meeting for NEO100 and Upcoming SNO Data Presentations

2026-11-12

Investivoq

NeOnc Technologies announces FDA meeting for NEO100, insider purchases, and upcoming presentations at the Society for Neuro-Oncology.

Investivoq AI Summary

NeOnc Technologies Holdings (NASDAQ: NTHI) is entering a crucial phase for its clinical programs with insider purchases and a significant upcoming FDA meeting regarding its brain cancer therapy NEO100. CEO Amir Heshmatpour recently increased his shareholding, buying 80,000 shares totaling approximately $333,100, while Chief Medical Officer Thomas Chen also made insider purchases. The FDA has scheduled a Type B End-of-Phase meeting for early January 2027 to discuss potential accelerated approval for NEO100, aiming to confirm that existing data supports a New Drug Application and to discuss the design of a pivotal Phase 3 trial. NeOnc also plans to provide updates at the Society for Neuro-Oncology conference. Analysts generally maintain a positive outlook on NeOnc’s clinical data, with several Buy ratings and price targets around $15-$20. Additionally, the company has established a collaboration with the Department of Health in Abu Dhabi for further clinical opportunities and research in pediatric oncology. Upcoming milestones include presentation data from the SNO meeting and feedback from the FDA meeting.

Potential Positives

Insider purchases by the CEO and Chief Medical Officer signal strong internal confidence in the company's future and the potential success of its clinical programs.
The FDA's decision to hold a Type B End-of-Phase meeting indicates potential pathways for accelerated approval of NEO100, which could expedite its market entry and enhance investor interest.
Positive Phase 2a clinical trial results for NEO100 show promising efficacy, with a significant six-month progression-free survival rate and no major toxicities, which may support favorable regulatory discussions and future approvals.
Analyst coverage remains bullish, with multiple firms maintaining Buy ratings and price targets significantly above the current share price, suggesting strong market confidence in the company’s future prospects.

Potential Negatives

The company has a growing short interest exceeding 920,000 shares, indicating potential negative sentiment and volatility in the stock, which could deter new investors.
The necessity of an FDA Type B End-of-Phase meeting implies that the company's drug development pathway is uncertain and may face regulatory challenges, creating risks for future approval and market entry.
The presence of insider purchases may indicate a lack of external confidence in the stock's performance, particularly if insiders feel compelled to buy shares at lower prices.

FAQ

What is the significance of NeOnc's FDA meeting for NEO100?

The FDA meeting scheduled for January 2027 aims to discuss an accelerated approval pathway for NEO100, a novel brain cancer therapy.

Who made recent insider purchases at NeOnc?

CEO Amir F. Heshmatpour and CMO Thomas C. Chen made notable insider purchases, totaling over $353,100 between them, signaling confidence in the company.

What are the upcoming milestones for NeOnc Technologies?

Key milestones include FDA feedback in early January 2027 and updated clinical data presentations on November 13, 2026, at the SNO meeting.

How does NEO100 compare to traditional cancer treatments?

NEO100 offers an intranasal delivery method, aimed at non-invasively targeting brain cancers, differing from conventional systemic therapies.

What role do analysts play in NeOnc's investment outlook?

Analysts provide ratings and price targets for NTHI, influencing market perceptions and highlighting expectations for upcoming clinical and regulatory milestones.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

EARLY ACCESS

Receive NTHI Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$NTHI Insider Trading Activity

$NTHI insiders have traded $NTHI stock on the open market 21 times in the past 6 months. Of those trades, 20 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $NTHI stock by insiders over the last 6 months:

AMIR F HESHMATPOUR (CEO, President) has made 12 purchases buying 261,000 shares for an estimated $982,464 and 0 sales.
THOMAS C CHEN (CMO) has made 7 purchases buying 64,830 shares for an estimated $269,998 and 0 sales.
KEITHLY GARNETT (CFO) has made 1 purchase buying 257 shares for an estimated $1,000 and 1 sale selling 5,000 shares for an estimated $16,809.

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$NTHI Hedge Fund Activity

We have seen 9 institutional investors add shares of $NTHI stock to their portfolio, and 13 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CINCTIVE CAPITAL MANAGEMENT LP added 181,938 shares (+12.8%) to their portfolio in Q2 2026, for an estimated $824,179
HUDSON BAY CAPITAL MANAGEMENT LP removed 147,360 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $667,540
MILLENNIUM MANAGEMENT LLC removed 119,249 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $540,197
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 91,036 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $412,393
683 CAPITAL MANAGEMENT, LLC removed 50,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $226,500
MORGAN STANLEY removed 36,275 shares (-69.9%) from their portfolio in Q2 2026, for an estimated $164,325
GOLDMAN SACHS GROUP INC removed 35,580 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $161,177

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$NTHI Price Targets

Multiple analysts have issued price targets for $NTHI recently. We have seen 3 analysts offer price targets for $NTHI in the last 6 months, with a median target of $15.0.

Here are some recent targets:

Thomas Shrader from BTIG set a target price of $15.0 on 05/26/2026
Matthew Venezia from Alliance Global Partners set a target price of $13.0 on 05/19/2026
Jason McCarthy from Maxim Group set a target price of $20.0 on 05/18/2026

Full Release

DENVER, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) is heading into a potentially important period for its clinical programs, with additional insider purchases coinciding with a newly announced FDA meeting that could help determine the development pathway for its investigational brain cancer therapy, NEO100.

Two Form 4 filings dated November 12 add important detail to the company's recent insider-buying activity. CEO Amir F. Heshmatpour reported purchasing 80,000 shares across November 19-11, including 50,000 shares at a weighted average price of $4.192, another 10,000 shares at $4.49, 10,000 shares at $4.00, and 10,000 shares at $3.86. The reported transactions represent approximately $333,100 in additional open-market purchases. His directly held common stock position increased to 3,333,000 shares following the transactions.

The latest filing follows a series of purchases throughout 2026, with the updated total 2026 purchases hitting approximately 341,000 shares.

The latest filings also show buying by another senior insider. Thomas C. Chen, the company's Chief Medical Officer, reported purchasing 2,732 shares on November 9 at $3.66 and another 2,284 shares on November 10 at a weighted average price of $4.379. The combined 5,016 shares represent approximately $20,000 in purchases through his IRA.

FDA meeting moves NEO100 toward a more defined regulatory discussion

The most significant recent development may be NeOnc's November 11 announcement that the FDA granted a Type B End-of-Phase meeting, scheduled for early January 2027, to discuss a potential accelerated approval pathway for intranasal NEO100.

This is more consequential than a routine regulatory update because the company intends to ask the FDA whether its existing clinical and nonclinical package could support a 505(b)(2) New Drug Application seeking accelerated approval under Section 506(c) of the Federal Food, Drug, and Cosmetic Act.

NeOnc also plans to seek agreement on the design of NEO100-012, a proposed multicenter, randomized, controlled Phase 3 study. The company describes the proposed trial as a comparison of intranasal NEO100 against investigator's-choice standard-of-care chemotherapy in patients with recurrent or progressive IDH-mutant grade 4 astrocytoma. Overall survival would serve as the primary endpoint.

Under the company's proposed strategy, a confirmatory Phase 3 trial would be underway, with enrollment ongoing, at the time of any accelerated-approval application. Its final overall survival analysis would then be intended to verify clinical benefit and support conversion to traditional approval.

NeOnc also intends to discuss the adequacy of its nonclinical safety package, the scientific bridge between published perillyl alcohol research and its intranasal formulation, and potential eligibility for Breakthrough Therapy designation.

These are important questions because regulatory feedback could influence the size, design, timing and cost of the next clinical-development stage.

The company has said it expects to provide an update after receiving and reviewing the FDA's official meeting minutes.

November 13 presentations could provide additional clinical detail

Another near-term catalyst is the 31st Annual Meeting of the Society for Neuro-Oncology (SNO), taking place November 12–15 in Philadelphia. NeOnc has announced two poster presentations scheduled for Friday, November 13, from 7:30 to 9:30 p.m. Eastern.

The first presentation, abstract CTNI-26, is titled "Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience."

Presented by Thomas C. Chen, MD, PhD, the poster is particularly relevant because it is intended to provide updated results combining the Phase 1/2a experience with compassionate-use observations. Investors and clinicians will be looking for additional information about the duration of responses, survival outcomes, patient characteristics and the consistency of the reported clinical experience.

The second presentation, abstract CTNI-27, is titled "Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity."

Presented by Josh Neman, PhD, the poster will address Phase 1 safety, pharmacokinetics and early signals of activity for NEO212, an investigational oral conjugate of temozolomide and perillyl alcohol.

This presentation matters because NEO212 represents a separate development opportunity from NEO100. While NEO100 is being evaluated as an intranasal therapy, NEO212 is designed as an oral approach for central nervous system cancers, including recurrent glioblastoma.

The clinical case: promising Phase 2a results

The regulatory discussion follows NeOnc's August 12 announcement of topline Phase 2a results for NEO100 in recurrent or progressive IDH1-mutant high-grade glioma.

NeOnc reported that the study achieved six-month progression-free survival of 48.9%, compared with a prespecified historical benchmark of 20%, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months.

The company reported no major toxicities across the cohort, with adverse events predominantly low-grade.

These results are relevant because recurrent IDH-mutant high-grade glioma remains a serious treatment challenge, and the company is seeking to develop an approach that delivers therapy intranasally rather than relying exclusively on conventional systemic administration.

NEO100 is a highly purified form of perillyl alcohol. Its intranasal delivery approach is designed to provide a non-invasive route to the brain.

Analyst coverage provides a key dimension to the investment picture

BTIG reiterated its Buy rating and maintained the $15 price target for NeOnc, reflecting continued confidence in the company's technology platform and clinical development opportunities. BTIG originally initiated coverage in April 2026, highlighting the potential of perillyl alcohol (POH) to improve drug delivery to the central nervous system, including its potential applications in glioblastoma and other aggressive brain cancers. The firm's research identified additional clinical data from NEO100 and NEO212 as important catalysts for the investment outlook.

BTIG is not alone in maintaining a positive view of NeOnc. Roth MKM analyst Jonathan Aschoff carries a Buy rating and $20 price target, Maxim Group analyst Jason McCarthy maintains a Buy rating and $20 target, while Alliance Global Partners analyst Matthew Venezia has a Buy rating and $13 target. This represents four analyst firms with Buy ratings and price targets ranging from $13 to $20. While analyst targets are opinions rather than predictions or guarantees of future performance, the coverage highlights the expectations being placed on NeOnc's upcoming clinical and regulatory milestones.

The short-interest angle adds another dimension

NTHI has also attracted attention from market participants tracking short interest.

The October 30 reporting period shows that the short interest has grown toto over 920,000 shares and over 7 days to cover, and it remains over 5 days to cover based on the corresponding average trading volume.

The company's relatively limited reported float compared with total shares outstanding is also relevant to potential volatility.

Abu Dhabi collaboration adds an international dimension

NeOnc has also announced a memorandum of understanding with the Department of Health – Abu Dhabi, signed in October 2026.

The proposed collaboration covers scientific exchange, specialist training, real-world evidence and an assessment of potential clinical trial opportunities in the emirate. The parties also intend to explore the possibility of a regional presence and future manufacturing, supply or distribution activities.

The company previously disclosed that two children in Abu Dhabi were receiving investigational NEO100 through its Compassionate Care program, with a third expected at the time of the announcement.

The agreement could create opportunities to expand clinical research and institutional relationships, particularly in pediatric oncology.

What investors should watch next

The coming weeks and months provide several identifiable milestones:

November 13, 2026: Updated NEO100 Phase 1/2a and compassionate-use data, alongside NEO212 Phase 1 safety, pharmacokinetic and early activity findings, at the SNO Annual Meeting.
Early January 2027: FDA Type B End-of-Phase meeting covering the potential accelerated approval pathway, proposed Phase 3 design, nonclinical safety package, scientific bridging and possible Breakthrough Therapy designation.
Following the FDA meeting: Publication and review of official FDA meeting minutes, which should provide greater clarity on regulatory feedback and the proposed clinical-development strategy.
Subsequent development: Progress toward the proposed NEO100-012 randomized Phase 3 trial, including final protocol requirements, funding, site activation and enrollment plans.

About 247MarketNews

In today's fast-moving markets, visibility is everything and 247MarketNews provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 247MarketNews delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247marketnews.com to discuss how 247MarketNews can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247MarketNews is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here . This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
247MarketNews
Editor@247marketnews.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.